CN-119936231-B - Plasma metabolism marker composition and screening method and application thereof

Abstract

The invention discloses a plasma metabolism marker composition, a screening method and application thereof, and relates to the technical field of biomedicine. The plasma metabolic marker composition comprises glycyl-L-glutamic acid, phosphatidylcholine 38:7, pyrrole-2-carboxylic acid and phosphatidylethanolamine 36:2p. The metabolic marker composition has obvious difference in different cancer types, can distinguish different cancer types of cancer patients, and realizes detection of the flood cancer types. The metabolic marker composition has noninvasive and minimally invasive performance when being used for detecting the flood cancer, is more suitable for screening and detecting large-scale common people, has higher sensitivity and specificity, is more suitable for early screening of cancers, is beneficial to early screening, early diagnosis and early treatment of cancers, and is beneficial to improving survival rate and cure rate of cancer patients.

Inventors

• LI YAN
• YU SHUQI
• SONG YINGYING
• SHI FEI
• SHAO TIANQI
• YANG RONGZHOU
• ZHANG TAO
• WEN HE
• Hu Juanyuan

Assignees

• 哈尔滨脉图精准技术有限公司

Dates

Publication Date

20260505

Application Date

20241230

Claims (9)

1. 1. A plasma metabolic marker composition comprising glycyl-L-glutamate, phosphatidylcholine 38:7, pyrrole-2-carboxylic acid and phosphatidylethanolamine 36:2p.
2. 2. The plasma metabolic marker composition according to claim 1, further comprising at least one of hypoxanthine, phosphatidylethanolamine 34:2p, phosphatidylethanolamine 36:1p, and pyroglutamic acid.
3. 3. The plasma metabolic marker composition according to claim 2, further comprising at least one of allantoic acid, phosphatidylethanolamine 36:3p, arabinose, oxalic acid, and phosphatidylcholine 34:2 e.
4. 4. The plasma metabolic marker composition according to claim 3, further comprising at least one of L-malic acid, nicotinic acid, oxalic acid, phosphatidylethanolamine 38:5p, and uridine.
5. 5. The plasma metabolic marker composition according to claim 3, wherein the plasma metabolic marker composition is composed of glycyl-L-glutamic acid, phosphatidylcholine 38:7, pyrrole-2-carboxylic acid, phosphatidylethanolamine 36:2p, hypoxanthine, phosphatidylethanolamine 34:2p, phosphatidylethanolamine 36:1p, pyroglutamic acid, allantoin, phosphatidylethanolamine 36:3p, arabinose, oxalic acid, and phosphatidylcholine 34:2 e.
6. 6. A method of screening a plasma metabolic marker composition according to any one of claims 1-5, comprising the steps of: Respectively extracting plasma of a gastric cancer patient, a colorectal cancer patient and a lung cancer patient to obtain an extracting solution; detecting an organic phase and a water phase in the extracting solution by using a chromatograph-mass spectrometer to obtain detection data; Performing data processing on the detection data, and then identifying metabolic products to obtain metabonomics data; analyzing the metabonomics data, and screening to obtain the plasma metabolic marker composition.
7. 7. The method of claim 6, wherein the step of analyzing the metabonomic data to screen for the plasma metabolic marker composition comprises: and carrying out linear correlation analysis on the metabonomics data, calculating to obtain a pearson correlation coefficient, and screening to obtain the plasma metabolic marker composition by taking the absolute value of the pearson correlation coefficient as a screening condition, wherein the absolute value of the pearson correlation coefficient is larger than a preset value.
8. 8. The screening method according to claim 7, wherein the absolute value of the pearson correlation coefficient is 0.3 or more as a screening condition.
9. 9. Use of a plasma metabolic marker composition according to any one of claims 1-5 for the preparation of a product for detecting a pan-carcinoma species, said pan-carcinoma species being gastric, colorectal or lung cancer.

Description

Plasma metabolism marker composition and screening method and application thereof Technical Field The invention relates to the technical field of biomedicine, in particular to a plasma metabolism marker composition, a screening method and application thereof. Background Cancer, which refers to a multi-stage process resulting from the transformation of normal cells into tumor cells, typically progresses from a precancerous lesion to a malignant tumor. Common cancer types mainly include lung cancer, colon and rectal cancer, stomach cancer, breast cancer, liver cancer, prostate cancer, etc., which have become major factors threatening the health of human beings. At present, clinically common cancer screening and diagnosis methods mainly comprise pathological examination, imaging examination, molecular screening and other modes. Pathological examination is a gold standard for cancer diagnosis, and is currently used in clinical work and scientific research in a large number. The pathological examination firstly can definitely and verify the preoperative diagnosis, improves the clinical diagnosis level, and secondly, after the diagnosis is definitely, can determine a further treatment scheme and estimate prognosis, further improves the clinical treatment level, and can obtain a large amount of valuable scientific research data. However, since pathology examinations are often invasive, this makes patient compliance low and not suitable for early screening of large populations. The imaging examination can provide images of the inside of the body, provide specific conditions such as lesion positions, sizes and the like, can help doctors diagnose diseases, determine the severity of the diseases and can provide monitoring after disease diagnosis for patients. But is also unsuitable for early screening of cancer because it has a certain emissivity and can be detected only when the lesion volume reaches a certain size. The noninvasive tumor markers commonly used in molecular screening are CEA, CA19-9 and the like, the sensitivity or specificity of the noninvasive tumor markers in cancer diagnosis is not high, and the detection result is easily influenced by various factors such as diet, medicines and lifestyle. Therefore, there is an urgent need to find new tumor markers that promote early intervention and treatment of cancer and extend the survival of patients. Metabolic markers, which are novel and hot in recent years, are mainly based on metabonomics, and are used for searching disease metabolic markers by revealing the overall metabolic change track under the influence of internal and external factors to reflect a series of biological events occurring in a certain pathophysiological process, and are one of the most widely used directions of metabonomics. Although highly specialized technology and equipment support is needed, data analysis is complex and the degree of standardization is relatively low, this method can improve the accuracy of diagnosis and has potential to be a tool for early diagnosis and prognosis evaluation of cancer. Accordingly, the prior art is still in need of improvement and development. Disclosure of Invention Based on the shortcomings of the prior art, the invention aims to provide a plasma metabolism marker composition, a screening method and application thereof, and aims to solve the problems of invasiveness or low accuracy of the existing method for diagnosing cancer. The technical scheme of the invention is as follows: in a first aspect of the invention, a plasma metabolic marker composition is provided, wherein the plasma metabolic marker composition comprises glycyl-L-glutamic acid, phosphatidylcholine 38:7, pyrrole-2-carboxylic acid, and phosphatidylethanolamine 36:2p. Optionally, the plasma metabolic marker composition further comprises at least one of hypoxanthine, phosphatidylethanolamine 34:2p, phosphatidylethanolamine 36:1p, and pyroglutamic acid. Optionally, the plasma metabolic marker composition further comprises at least one of allantoin, phosphatidylethanolamine 36:3p, arabinose, oxalic acid, and phosphatidylcholine 34:2 e. Optionally, the plasma metabolic marker composition further comprises at least one of L-malic acid, nicotinic acid, oxalic acid, phosphatidylethanolamine 38:5p, and uridine. Alternatively, the plasma metabolic marker composition is comprised of glycyl-L-glutamic acid, phosphatidylcholine 38:7, pyrrole-2-carboxylic acid, phosphatidylethanolamine 36:2p, hypoxanthine, phosphatidylethanolamine 34:2p, phosphatidylethanolamine 36:1p, pyroglutamic acid, allantoin, phosphatidylethanolamine 36:3p, arabinose, oxalic acid, and phosphatidylcholine 34:2 e. In a second aspect of the present invention, there is provided a method for screening a plasma metabolic marker composition according to the present invention as described above, comprising the steps of: Respectively extracting plasma of a gastric cancer patient, a colorectal cancer patient and a lung cancer patient